RELIGRAST 300MCG ING

About

Religrast 300mcg Injection is a recombinant human granulocyte colony-stimulating factor (G-CSF) that plays a crucial role in stimulating the production, maturation, and activation of neutrophils from the bone marrow. Neutrophils are a type of white blood cell essential for fighting bacterial and fungal infections. By increasing neutrophil counts, Religrast helps to reduce the incidence and duration of neutropenia, a condition characterized by abnormally low levels of neutrophils, which often occurs as a side effect of myelosuppressive chemotherapy or in patients undergoing bone marrow transplantation. This medication works by binding to specific receptors on hematopoietic stem cells and progenitor cells, promoting their proliferation and differentiation into mature neutrophils. Its therapeutic action is vital in mitigating the risk of severe infections in immunocompromised patients, thereby improving their clinical outcomes and allowing for the continuation of critical cancer treatments.

Uses

• Prevention of chemotherapy-induced neutropenia
• Mobilization of peripheral blood stem cells
• Treatment of severe chronic neutropenia
• Reduction of infection risk post-bone marrow transplant

Directions For Use

Administered subcutaneously or intravenously by a healthcare professional. Dosage and frequency are determined by the physician based on the patient's condition.

Benefits

• Reduces the risk of serious infections
• Shortens the duration of neutropenia
• Supports continuation of chemotherapy cycles
• Enhances recovery after bone marrow transplantation
• Improves immune system function
• Facilitates stem cell collection for transplantation

Side Effects

• Bone pain
• Fever
• Fatigue
• Nausea
• Headache
• Alopecia
• Diarrhea
• Rash
• Splenomegaly
• Injection site reactions
• Allergic reactions
• Acute respiratory distress syndrome (rare)

Safety Measures

• Alcohol - No direct interaction, but alcohol can weaken the immune system, which is counterproductive when using G-CSF.
• Pregnancy - Use only if clearly needed; potential risks to the fetus are not fully established. Consult your doctor.
• Breastfeeding - Unknown if excreted in human milk; caution advised. Discuss with your healthcare provider.
• Liver - No specific dose adjustment needed, but monitor patients with severe hepatic impairment.
• Kidney - No specific dose adjustment needed, but monitor patients with severe renal impairment.
• Lung - Rare cases of acute respiratory distress syndrome (ARDS) have been reported; monitor for pulmonary symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.